3 days Ago By ABMN Staff
AtriCure ( NASDAQ:ATRC – Get Free Report ) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Saturday. Several other equities analysts have also recently commented on the stock.
Needham & Company LLC lowered their target price on shares of AtriCure from $40.00 to $34.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st.
Stifel Nicolaus reduced their target price on AtriCure from $30.00 to $26.00 and set a “buy” rating for the company in a report on Wednesday, July 31st.
BTIG Research decreased their price objective on shares of AtriCure from $58.00 to $53.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st.
Piper Sandler lowered their target price on AtriCure from $65.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st.
Finally, JPMorgan Chase & Co. dropped their price target on shares of AtriCure from $34.00 to $30.
00 and set an “overweight” rating on the stock in a research note on Wednesday, July 31st. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.
com, AtriCure currently has an average rating of “Moderate Buy” and an average price target of $42.44. View Our Latest Report on AtriCure AtriCure Trading Up 1.
8 % AtriCure ( NASDAQ:ATRC – Get Free Report ) last posted its quarterly earnings results on Tuesday, July 30th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.
17). The company had revenue of $116.27 million for the quarter, compared to the consensus estimate of $116.
24 million. AtriCure had a negative net margin of 9.33% and a negative return on equity of 8.
39%. The company’s revenue for the quarter was up 15.2% on a year-over-year basis.
During the same period last year, the firm posted ($0.12) EPS. As a group, research analysts predict that AtriCure will post -0.
77 earnings per share for the current fiscal year. Insider Activity at AtriCure In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $24.
07, for a total transaction of $84,245.00. Following the completion of the sale, the director now directly owns 8,970 shares in the company, valued at $215,907.
90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink . 3.
20% of the stock is owned by company insiders. Institutional Investors Weigh In On AtriCure A number of hedge funds have recently made changes to their positions in the stock. Hood River Capital Management LLC acquired a new position in shares of AtriCure during the second quarter worth $40,422,000.
First Light Asset Management LLC lifted its stake in AtriCure by 42.1% in the second quarter. First Light Asset Management LLC now owns 1,964,703 shares of the medical device company’s stock valued at $44,736,000 after buying an additional 581,843 shares during the period.
Champlain Investment Partners LLC boosted its stake in AtriCure by 27.3% during the first quarter. Champlain Investment Partners LLC now owns 2,681,000 shares of the medical device company’s stock worth $81,556,000 after acquiring an additional 575,605 shares in the last quarter.
Millennium Management LLC grew its stake in shares of AtriCure by 132.5% in the 2nd quarter. Millennium Management LLC now owns 952,765 shares of the medical device company’s stock valued at $21,694,000 after buying an additional 543,023 shares during the period.
Finally, Natixis bought a new stake in shares of AtriCure during the first quarter valued at approximately $9,126,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.
AtriCure Company Profile ( Get Free Report ) AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. Recommended Stories Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.
com's FREE daily email newsletter ..
